Special Feature: Special Report
Gastrointestinal Outcomes and Confounders in Cystic Fibrosis
Drucy Borowitz,
Peter R Durie,
Lane L Clarke,
Steven L Werlin,
Christopher J Taylor,
John Semler,
Robert C De Lisle,
Peter Lewindon,
Steven M Lichtman,
Maarten Sinaasappel,
Robert D Baker,
Susan S Baker,
Henkjan J Verkade,
Mark E Lowe,
Virginia A Stallings,
Morteza Janghorbani,
Ross Butler,
James Heubi,
Drucy Borowitz
Search for more papers by this authorPeter R Durie
Search for more papers by this authorLane L Clarke
Search for more papers by this authorSteven L Werlin
Search for more papers by this authorChristopher J Taylor
Search for more papers by this authorJohn Semler
Search for more papers by this authorRobert C De Lisle
Search for more papers by this authorPeter Lewindon
Search for more papers by this authorSteven M Lichtman
Search for more papers by this authorMaarten Sinaasappel
Search for more papers by this authorRobert D Baker
Search for more papers by this authorSusan S Baker
Search for more papers by this authorHenkjan J Verkade
Search for more papers by this authorMark E Lowe
Search for more papers by this authorVirginia A Stallings
Search for more papers by this authorMorteza Janghorbani
Search for more papers by this authorRoss Butler
Search for more papers by this authorJames Heubi
Search for more papers by this authorDrucy Borowitz,
Peter R Durie,
Lane L Clarke,
Steven L Werlin,
Christopher J Taylor,
John Semler,
Robert C De Lisle,
Peter Lewindon,
Steven M Lichtman,
Maarten Sinaasappel,
Robert D Baker,
Susan S Baker,
Henkjan J Verkade,
Mark E Lowe,
Virginia A Stallings,
Morteza Janghorbani,
Ross Butler,
James Heubi,
Drucy Borowitz
Search for more papers by this authorPeter R Durie
Search for more papers by this authorLane L Clarke
Search for more papers by this authorSteven L Werlin
Search for more papers by this authorChristopher J Taylor
Search for more papers by this authorJohn Semler
Search for more papers by this authorRobert C De Lisle
Search for more papers by this authorPeter Lewindon
Search for more papers by this authorSteven M Lichtman
Search for more papers by this authorMaarten Sinaasappel
Search for more papers by this authorRobert D Baker
Search for more papers by this authorSusan S Baker
Search for more papers by this authorHenkjan J Verkade
Search for more papers by this authorMark E Lowe
Search for more papers by this authorVirginia A Stallings
Search for more papers by this authorMorteza Janghorbani
Search for more papers by this authorRoss Butler
Search for more papers by this authorJames Heubi
Search for more papers by this authorThis workshop was sponsored by the Cystic Fibrosis Foundation.
Individual authors were supported by National Institutes of Health grants DK048816 (LLC), DK 56791 (RCD), HD 033060 and DK 053100 (MEL), R42 DK48537 and R44 DK48190 (MJ) and Sheffield Children's Hospital Charity, Special Trustees Sheffield Hospitals Charitable Trust, Cystic Fibrosis Trust (CJT), and Solvay Pharmaceuticals (RB).
JS is compensated and has an equity position in SmartPill™. MJ is the president and part owner of BioChemAnalysis Corporation.
For all Participants of the Cystic Fibrosis Foundation Workshop
REFERENCES
- 1FitzSimmons SC, Burkhart GA, Borowitz DS, et al. High-dose pancreatic enzyme supplements and fibrosing colonopathy in children with CF. N Engl J Med 1997; 336: 1283–9.
- 2Federal Register, Vol. 69, No. 82(Docket 2003N-0205), pp. 23410–4. Available at: www.fda.gov/cder/guidance/index.htm.
- 3Durie P, Kalnins D, Ellis L. Uses and abuses of enzyme therapy in cystic fibrosis. J Royal Soc Med 1997; 91(Suppl 34): 2–13.
- 4Baker SS, Borowitz D, Duffy L, et al. Pancreatic enzyme therapy and clinical outcomes in patients with cystic fibrosis. J Pediatr 2005; 146: 189–93.
- 5Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000; 67: 117–33.
- 6Couper RTL, Corey M, Moore DJ, et al. Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency. Pediatr Res 1992; 32: 179–82.
- 7Zielinski J, Corey M, Rozmahel R, et al. Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet 1999; 22: 128–9.
- 8Knowles MR, Konstan M, Schluchter M, et al. CF gene modifiers: comparing variation between unrelated individuals with different pulmonary phenotypes. Pediatr Pulmonol 2004;(Suppl 27): 139–40.
- 9Davidson DJ and Dorin Jr. The CF mouse: an important tool for studying cystic fibrosis. Exp Rev Mol Med 2001; 12: 1–27.
10.1017/S1462399401002575 Google Scholar
- 10Grubb BR, Boucher RC. Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev 1999; 79: S193–214.
- 11Bijvelds MJC, Bronsveld I, Havinga R, et al. Fat absorption in cystic fibrosis mice is impeded by defective lipolysis and post-lipolytic events. Am J Physiol Gastrointest Liver Physiol 2005; 288: G646–53.
- 12Clarke LL, Harline MC. Dual role of CFTR in cAMP-stimulated HCO3 secretion across murine duodenum. Am J Physiol 1998; 274 (4 Pt 1): G718–726.
- 13Pratha VS, Hogan DL, Martensson BA, et al. Identification of transport abnormalities in duodenal mucosa and duodenal enterocytes from patients with cystic fibrosis. Gastroenterology 2000; 118: 1051–60.
- 14Clarke LL, Stien X, Walker NM. Intestinal bicarbonate secretion in CF mice. J Pancreas 2001; 2(Suppl 4): 263–7.
- 15Gawenis LR, Franklin CL, Simpson JE, et al. cAMP inhibition of murine intestinal Na+/H+ exchange requires CFTR-mediated cell shrinkage of villus epithelium. Gastroenterology 2003; 125: 1148–63.
- 16Rozmahel R, Wilschanski M, Matin A, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 1996; 12: 280–7.
- 17Kent G, Oliver M, Foskett JK, et al. Phenotypic abnormalities in long-term surviving cystic fibrosis mice. Pediatr Res 1996; 40: 233–41.
- 18Durie PR, Kent G, Phillips MJ, Ackerly CA. Characteristic multiorgan pathology of CF in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol 2004; 164: 1481–93.
- 19Norkina O, Kaur S, Ziemer D, De Lisle RC. Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2004; 286: G1032–41.
- 20Clarke LL, Gawenis LR, Bradford EM, et al. Abnormal Paneth cell granule dissolution and compromised resistance to bacterial colonization in the intestine of CF mice. Am J Physiol Gastrointest Liver Physiol 2004; 286: G1050–8.
- 21Gallagher AM, Gottlieb RA. Proliferation, not apoptosis, alters epithelial cell migration in small intestine of CFTR null mice. Am J Physiol 2001; 281: G681–7.
- 22Freedman SD, Katz MH, Parker EM, et al. A membrane-lipid imbalance plays a role in the phenotypic expression of CF in cftr−/− mice. Proc Natl Acad Sci U S A 1999; 96: 13995–4000.
- 23Werner A, Bongers ME, Bijvelds MJ, et al. No indications for altered essential fatty acid metabolism in two murine models for cystic fibrosis. J Lipid Res 2004; 45: 2277–86.
- 24Hardcastle J, Harwood MD, Taylor CJ. Small intestinal glucose absorption in cystic fibrosis: a study in human and transgenic ΔF508 cystic fibrosis mouse tissues. J Pharm Pharmacol 2004; 56: 329–38.
- 25Turner JR, Black ED. NHE3-dependent cytoplasmic alkalinization is triggered by Na+-glucose cotransport in intestinal epithelia. Am J Physiol 2001; 281: C1533–41.
- 26Ganapathy V, Ganapathy ME, Leibach FH. Intestinal transport of peptides and amino acids. In: KE Barrett and M Donowitz, eds. Gastrointestinal Transport Molecular Physiology (Current Topics in Membranes, Vol. 50). San Diego: Academic Press 2001: 379–412.
- 27Gawenis LR, Hut H, Bot AGM, et al. Electroneutral sodium absorption and electrogenic anion secretion across murine small intestine are regulated in parallel. Am J Physiol 2004; 287: G1140–9.
- 28Roulet M, Weber AM, Paradis Y, et al. Gastric emptying and lingual lipase activity in cystic fibrosis. Pediatr Res 1980; 14: 1360–2.
- 29Cavell B. Gastric emptying in infants with cystic fibrosis. Acta Paediatr Scand 1981; 70: 635–8.
- 30Smith HL, Hollins GW, et al. Gastric emptying of liquids in cystic fibrosis. Acta Universitatis Carolinae - Medica 1990; 36: 161–4.
- 31Carney BI, Jones KL, et al. Gastric emptying of oil and aqueous meal components in pancreatic insufficiency: effects of posture and on appetite. Am J Physiol 1995; 268(6 Pt 1): G925–32.
- 32Cucchiara S, Raia V, Horowitz M, et al. Ultrasound measurement of gastric emptying time in patients with cystic fibrosis and effect of ranitidine on delayed gastric emptying. Pediatr 1996; 128: 485–8.
- 33Collins CE, Francis JL, Thomas P, et al. Gastric emptying time is faster in cystic fibrosis. J Pediatr Gastroenterol Nutr 1997; 25: 492–8.
- 34Symonds E, Omari T, Webster JM, et al. Relation between pancreatic lipase activity and gastric emptying rate in children with cystic fibrosis. J Pediatr 2003; 143: 772–5.
- 35Armand M, Hamosh M, Philpott JR, et al. Gastric function in children with cystic fibrosis: effect of diet on gastric lipase levels and fat digestion. Pediatr Res 2004; 55: 457–65.
- 36Taylor CJ, Hillel PG, Ghosal S, et al. Gastric emptying and intestinal transit of pancreatic enzyme supplements in cystic fibrosis. Arch Dis Child 1999; 80: 149–52.
- 37Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M, Figueiras A, Vilarino-Insua M. Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: a randomized, three-way crossover study. Aliment Pharmacol Ther 2005; 21: 993–1000.
- 38DiMagno EP. Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency. Best Pract Res Clin Gastroenterol 2001; 15: 477–86.
- 39Proesmans M, De Boeck K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur J Pediatr 2003; 162: 760–3.
- 40Tso P. Intestinal lipid absorption. In: LR Johnson, ed. Physiology of the Gastrointestinal Tract. New York: Raven Press, 1994; 1867–1907.
- 41Lowe ME. The triglyceride lipases of the pancreas. J Lipid Res 2002; 43: 2007–16.
- 42Kalivianakis M, Minich DM, Bijleveld CMA, et al. Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids. Am J Clin Nutr 1999; 69: 127–34.
- 43Innis SM, Davidson GF, Chen A, et al. Increased plasma homocysteine and s-adenosylhomocysteine and decreased methionine is associated with altered phosphatidylcholine and phosphatidylethanolamine in cystic fibrosis. J Pediatr 2003; 143: 351–6.
- 44O'Brien S, Mulcahy H, Fenlon H, et al. Intestinal bile acid malabsorption in cystic fibrosis. Gut 1993; 34: 1137–41.
- 45Van Biervliet S, Eggermont E, Marien P, Hoffman I, Veereman G. Combined impact of mucosal damage and of cystic fibrosis on the small intestinal brush border enzyme activities. Acta Clin Belg 2003; 58: 220–4.
- 46Pelton NS, Tivey DR, Howarth GS, Davidson GP, Butler RN. A novel breath test for the non-invasive assessment of small intestinal mucosal injury following methotrexate administration in the rat. Scand J Gastroenterol 2004; 39: 1015–6.
- 47Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Gastroenterol Rep 2003; 5: 365–72.
- 48Lewindon PJ, Robb TA, Moore DJ, Davidson GP, Martin AJ. Bowel dysfunction in cystic fibrosis: importance of breath testing. J Paediatr Child Health 1998; 34: 79–82.
- 49Fridge J, Castillo R, Conrad C, Gerson L, Cox K. Small bowel bacterial overgrowth in cystic fibrosis. Gastroenterol 2005; 128 (Suppl 2): S1025.
- 50Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice. Am J Gastroenterol 2002; 97: 1113–26.
- 51Lichtman S. Bacterial overgrowth. In: WA Walker, PR Durie, JR Hamilton, JA Walker-Smith, JB Watkins, eds. Pediatric Gastrointestinal Disease, 4th ed. Philadelphia: BC Decker Inc.; 2004: 569–82.
- 52Riordan SM, McIver CJ, Walker BM, et al. The lactulose breath hydrogen test of SBBO. Am J Gastroenterol 1996; 91: 1795–803.
- 53Amarri S, Coward WA, Harding M, Weaver LT. Importance of measuring CO2-production rate when using 13C-breath tests to measure fat digestion. Br J Nutrit 1998; 79: 541–5.
- 54Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 2004; 72: 6040–9.
- 55Roberts DM, Craft JC, Mather FJ, Davis SH, Wright JA. Prevalence of giardiasis in patients with cystic fibrosis. J Pediatr 1988; 112: 555–9.
- 56Welkon CJ, Long SL, Thompson M, Gilligan PH. Clostridium difficile in patients with cystic fibrosis. Am J Dis Child 1985; 139: 805–8.
- 57Wu TC, McCarthy VP, Gill VJ. Isolate rate and toxigenic potential of clostridium difficile isolates from patients with cystic fibrosis. J Infect Dis 1983; 148: 176.
- 58Lloyd-Still J. Crohn's disease and cystic fibrosis. Dig Dis Sci 1994; 39: 880–5.
- 59Hill ID, Dirks MH, Liptak GS, et al. Guidelines for the diagnosis and treatment of celiac disease in children: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2004; 40: 1–19.
- 60Elson CO, Ballew M, Barnard JA, et al. National Institutes of Health Consensus Development Conference Statement: Celiac Disease. June 28-30, 2004. Available at: http://consensus.nih.gov/cons/118/118cdc_intro.htm.
- 61Farrell RJ, Kelly CP. Diagnosis of celiac sprue. Am J Gastroenterol 2001; 96: 3237–46.
- 62Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003; 163: 286–92.
- 63MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005; 307: 1920–25.
- 64Ruemelle FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterol 1998; 115: 822–29.
- 65Borowitz D, Goss CH, Stevens C, et al. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation, TheraCLEC-Total, containing pancrease, lipase and amylase for the treatment of exocrine pancreatic insufficiency. Pediatr Pulmonol 2003;Suppl 25: 339.
- 66Stern RC, Eisenberg JD, Wagener JS, et al. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical pancreatic insufficiency. Am J Gastroenterol 2000; 95: 1932–8.
- 67Konstan MW, Stern RC, Trout JR, et al. Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy. Aliment Pharmacol Ther 2004; 20: 1365–71.
- 68Goldstein R, Blondheim O, Levy E, Stankiewicz H, Freier S. The fatty meal test: an alternative to stool fat analysis. Am J Clin Nutr 1983; 38: 763–8.
- 69Stallings VA, Schall JI, Mascarenhas M. Malabsorption blood test (MBT): a novel approach to quantify steatorrhea. Pediatr Pulmonol 2003;(Suppl 25):338.
- 70Davidson GP, Butler RN. Breath tests in pediatric gastroenterology. In: A Walker, P Durie, J Hamilton, J Walker-Smith, eds. Pediatric Gastrointestinal Disease, 3rd ed. Philadelphia: BC Deker, Inc. 2000: 1529–37.
- 71Ghoos YF, Maes BD, Geypens BJ, et al. Measurement of gastric emptying rate of solid by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993; 104: 1640–47.
- 72Ghoos YF, Vantrappen GR, Rutgeerts PJ, Schurmans PC. A mixed- triglyceride breath test for intraluminal fat digestive activity. Digestion 1981; 22: 239–47.
- 73Ritz MA, Fraser RJ, Di Matteo AC, et al. Evaluation of the 13C-triolein breath test for fat malabsorption in adult patients with cystic fibrosis. J Gastroenterol Hepatol 2004; 19: 448–53.
- 74Kalivianakis M, Elstrodt J, Havinga R, et al. Validation in an animal model of the carbon 13-labeled mixed triglyceride breath test for the detection of intestinal fat malabsorption. J Pediatr 1999; 135: 444–50.
- 75Schuette SA, Janghorbani M, Young VR, Weaver CM. Dysprosium as a nonabsorbable marker for studies of mineral absorption with stable isotopes tracers in human subjects. J Am Coll Nutr 1993; 12: 307–15.
- 76Schuette SA, Janghorbani M, Cohen MB, et al. Dysprosium chloride as a nonabsorbable gastrointestinal marker for studies of stable-isotope-labeled triglyceride excretion in man. J Am Coll Nutr 2003; 22: 379–87.
- 77Schuette SA, Janghorbani M, Cohen MB, et al. Effect of triglyceride structure on fecal excretion of 13C-labeled triglycerides. J Am Coll Nutr 2003; 22: 511–18.
- 78Metcalfe LD, Schmitz AA, Pelka JR. Rapid preparation of fatty acid esters from lipids for gas chromatographic analysis. Anal Chem 1966; 38: 514–5.
- 79Jandacek RJ, Heubi JE, Tso P. A novel, noninvasive method for measurement of intestinal fat absorption. Gastroenterology 2004; 127: 139–44.
Citing Literature
